ERBB2 and breast cancer: Preliminary results from a Phase II study (DAISY) reported a response rate of 30.6% to T-DXd treatment in BC patients with HER2 IHC score of 0 (vs. 69.1% in HER2-positve tumors, 33.3% in HER2-low tumors) [56].